Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 10.93 1.30% 0.14
STML closed up 1.3 percent on Monday, September 16, 2019, on 1.2 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical STML trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Bullish Engulfing Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 1.30%
Down 3 Days in a Row Weakness 1.30%
Down 4 Days in a Row Weakness 1.30%

Older signals for STML ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Biopharmaceutical Cancer Biology Stem Cells Tumor Platform Technology Refractory Acute Myeloid Leukemia Carcinogenesis Cancer Stem Cell Cancer Stem Cells
Is STML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 18.22
52 Week Low 7.82
Average Volume 576,224
200-Day Moving Average 12.7462
50-Day Moving Average 13.3916
20-Day Moving Average 12.1165
10-Day Moving Average 11.193
Average True Range 0.7911
ADX 25.1
+DI 13.8283
-DI 26.7087
Chandelier Exit (Long, 3 ATRs ) 13.2967
Chandelier Exit (Short, 3 ATRs ) 12.9033
Upper Bollinger Band 14.5819
Lower Bollinger Band 9.6511
Percent B (%b) 0.26
BandWidth 40.69492
MACD Line -0.8625
MACD Signal Line -0.7908
MACD Histogram -0.0717
Fundamentals Value
Market Cap 256.36 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -4.43
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.40
Resistance 3 (R3) 11.39 11.22 11.32
Resistance 2 (R2) 11.22 11.11 11.23 11.29
Resistance 1 (R1) 11.08 11.03 11.15 11.09 11.27
Pivot Point 10.91 10.91 10.95 10.92 10.91
Support 1 (S1) 10.77 10.79 10.84 10.77 10.59
Support 2 (S2) 10.60 10.72 10.61 10.57
Support 3 (S3) 10.46 10.60 10.54
Support 4 (S4) 10.46